FluidForm is led by a team with deep expertise in additive manufacturing, medical technology, and high tech.
Mike Graffeo, CEO
A senior executive with a proven track record in commercialization of innovative medical technology, Mike is a results-oriented, decisive leader with a track record of successfully growing new businesses in both startup and growth organizations. Throughout his career, he has gained extensive experience translating highly complex devices and clinical data into successful businesses, both in the US and globally. Mike holds a BS in Engineering Physics and an MEng in Mechanical Engineering from Cornell University, as well as an MBA from Harvard Business School.
Adam Feinberg, Chief Technology officer
Dr. Adam Feinberg is CTO and co-founder of FluidForm. The core technology of FRESH printing was developed in his Regenerative Biomaterials and Therapeutics lab at Carnegie Mellon University (CMU), where he is an Associate Professor in the Departments of Biomedical Engineering and Materials Science and Engineering. His group develops materials-based, engineering strategies to control the self-organization and assembly of various cell types into tissues.
Adam earned his Bachelor of Science in Materials Science and Engineering from Cornell University, and his MS and PhD in Biomedical Engineering from the University of Florida. He performed his postdoctoral work at the School of Engineering and Applied Science at Harvard University. He holds more than 20 US patents and patent applications, has authored over 45 publications, and is a member of the Materials Research Society, American Chemical Society, Society for Biomaterials, Biophysical Society, Biomedical Engineering Society, and the American Heart Association.
Andrew Hudson, Chief Operations Officer
Andrew is a co-founder of FluidForm and leads the development, manufacturing and scale-up efforts of LifeSupport™. His research focuses on developing the next generation of techniques for vascularizing 3D-bioprinted tissues to improve the clinical translational potential of tissue engineered therapies.
Rickey Kallicharan, Global Head of Business Development
Rickey leads the company’s business development, strategy, and commercial execution efforts. He has over 10 years of experience that include business development, sales, national accounts, market development and hospital administration. Most recently, he was Director of Business & Market Development at PolarityTE. Before that, he worked in various commercial leadership roles for large and start-up organizations including Insulet, Acclarent (acquired by Johnson & Johnson), Medrobotics, and Hackensack Meridian Health. Mr. Kallicharan earned an MBA with a concentration in healthcare management and a BS in Biology from Monmouth University in NJ.
Chris Sandini, Solutions Lead
As FluidForm’s Solutions Lead, Chris is responsible for developing FRESH solutions for various industry challenges. Chris joined FluidForm in April 2019 from Insulet Corporation, where he oversaw and managed all aspects of the Amgen On-body Injector program for Neulasta. He has over 10 years of Medical Industry experience in areas that include Quality, Manufacturing, and Program Management of Drug Delivery and Orthopedic Devices. Chris earned a BS in Mechanical Engineering from Wentworth Institute of Technology in Boston, MA.